ICLR$167.91
$168.84
Chart
Performance
Key Stats
AI ICLR Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
Strong BuyICON PLC demonstrates strong fundamental performance with robust profitability and a healthy balance sheet. The company is well-positioned within the growing clinical research sector. Technicals show a strong uptrend with some short-term overbought conditions.
Thematic
ICON PLC operates in the clinical research sector, benefiting from increased outsourcing by pharmaceutical and biotech companies, and the growing demand for decentralized and hybrid clinical trials.
Fundamental
ICON PLC exhibits strong revenue growth and improving profitability, supported by a solid balance sheet and consistent free cash flow generation. Valuation metrics are reasonable given its growth profile.
Technical
The stock is exhibiting a strong upward trend, trading above key moving averages. Momentum indicators suggest continued strength, though some are approaching overbought levels.
| Factor | Score |
|---|---|
| Outsourcing Trend in Pharma/Biotech | 85 |
| Decentralized & Hybrid Trials | 80 |
| Drug Development Pipeline Growth | 70 |
| Regulatory Landscape | 65 |
| Competitive Intensity | 75 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 70 |
| Growth | 70 |
| Balance Sheet Health | 80 |
| Cash Flow | 90 |
| Earnings Surprise | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 70 |
| Volume | 75 |
| Support & Resistance | 70 |
| MACD | 85 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprises
The company has exceeded earnings per share (EPS) estimates in the latest reported quarter (Q2 2025) with reported EPS of $3.19 versus an estimate of $3.12, indicating a positive surprise of 2.23%.
Reasonable P/E Ratio
The trailing twelve months (TTM) Price-to-Earnings (P/E) ratio is 20.08, which is generally considered reasonable for a company in the clinical research organization sector, especially considering its historical performance and future growth prospects.
Bearish Points (8)
Elevated Quarterly P/E Ratio
The most recent quarterly P/E ratio for 2025 Q1 is 88.3, which is significantly high and may suggest that the stock is currently overvalued based on short-term earnings.
Missed Earnings Expectations
The company missed earnings per share (EPS) estimates in Q4 2024, reporting $3.35 against an estimate of $3.84, a negative surprise of -12.7%, which could signal underlying operational challenges.
Calendar
July 2025
24
Next Earnings Date
H: $3.51
A: $3.33
L: $3.22
H: 2.03B
A: 1.99B
L: 1.95B
Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Seasonals
Price Target
203.33 USD
The 39 analysts offering 1 year price forecasts for ICLR have a max estimate of 243.00 and a min estimate of 144.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Dominant provider of GPUs essential for training deep learning models, significant contributions to AI software platforms (CUDA, cuDNN), and extensive AI research.
Weight: 98
Parent company of Google Brain and DeepMind, leading AI research labs; developer of TensorFlow, a widely used open-source ML framework; extensive cloud AI services (Google Cloud AI).
Weight: 97
Strategic partnership with OpenAI, extensive AI research and development through Microsoft Research, Azure AI cloud services, and deep integration of AI (e.g., Copilot) across its product ecosystem.
Weight: 95
Amazon Web Services (AWS) offers a vast suite of AI/ML services (e.g., SageMaker, Rekognition, Bedrock), extensive application of AI in e-commerce, logistics, and voice AI (Alexa).